Suchergebnisse - "Wei, Xue-Wu"

PubPharm (17)

1

Allelic Context of EGFR C797X-Mutant Lung Cancer Defines Four Subtypes With Heterogeneous Genomic Landscape and Distinct Clinical Outcomes

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2024

von Lu, C. | Wei, X. | Wang, Z. | +23

2

Redoxhigh phenotype mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes tissue-resident memory CD8+ T cells and attenuates the efficacy of immunotherapy in lung adenocarcinoma

enthalten in: Oncoimmunology | 2024

von Wei, X. | Lu, C. | Zhang, Y. | +17

3

Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8) : a multi-center, single-arm, phase 2 trial

enthalten in: EClinicalMedicine | 2023

von Maggie Liu, S. | Dong, X. | Wang, Z. | +23

4

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer : a patient-centric phase 2 trial

enthalten in: Nature medicine | 2023

von Liu, S. | Tu, H. | Wei, X. | +27

CommentIn: Nat Med. 2023 Aug;29(8):1908-1909. - PMID 37524954

5

Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer

enthalten in: Journal for immunotherapy of cancer | 2023

von Deng, J. | Gou, Q. | Yang, L. | +11

6

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

enthalten in: Journal of cancer research and clinical oncology | 2023

von Lu, C. | Wei, X. | Zhang, Y. | +6

7

Biomarker-Driven Studies With Multi-targets and Multi-drugs by Next-Generation Sequencing for Patients With Non-Small-Cell Lung Cancer : An Open-Label, Multi-center, Phase II Adaptive Umbrella Trial and a Real-World Observational Study (CTONG1702&CTONG1705)

enthalten in: Clinical lung cancer | 2022

von Liu, S. | Yan, H. | Wei, X. | +15

8

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

enthalten in: Journal of cancer research and clinical oncology | 2022

von Lu, C. | Wei, X. | Zhang, Y. | +6

9

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

enthalten in: Journal of cancer research and clinical oncology | 2022

von Lu, C. | Wei, X. | Zhang, Y. | +6

10

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes

enthalten in: Journal of cancer research and clinical oncology | 2022

von Lu, C. | Wei, X. | Zhang, Y. | +6